XORTX Therapeutics Inc.
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
XRTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- CA98420Q2071
- LEI:
- Country:
- United States of America
- Address:
- SUITE 2400 - 745 THURLOW STREET, VANCOUVER
- Website:
- https://www.xortx.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing first-in-class, uric acid-lowering agents. The company's therapeutic pipeline targets diseases modulated by aberrant purine and uric acid metabolism, primarily focusing on gout and progressive kidney diseases. Its lead programs include XRx-026 for gout patients unresponsive to standard care, which is at the pre-New Drug Application (NDA) filing stage. Other key development programs are XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney disease, and XRx-225 for Type 2 Diabetic Nephropathy (T2DN). XORTX actively pursues strategic collaborations to develop and commercialize its novel therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all XORTX Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XORTX Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XORTX Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
